Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Metal complexes of bleomycin: evaluation of [Rh-105]-bleomycin for use in targeted radiotherapy.

Brooks RC, Carnochan P, Vollano JF, Powell NA, Zweit J, Sosabowski JK, Martellucci S, Darkes MC, Fricker SP, Murrer BA.

Nucl Med Biol. 1999 May;26(4):421-30.

PMID:
10382846
2.

cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.

Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.

Clin Cancer Res. 1997 Nov;3(11):2063-74.

3.

Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).

Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley JA, Abrams M, Kelland LR.

Anticancer Drug Des. 1998 Jan;13(1):1-18.

PMID:
9474239
4.

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.

Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR.

Br J Cancer. 1998;77(3):366-73.

5.

Ruthenium complexes as nitric oxide scavengers: a potential therapeutic approach to nitric oxide-mediated diseases.

Fricker SP, Slade E, Powell NA, Vaughan OJ, Henderson GR, Murrer BA, Megson IL, Bisland SK, Flitney FW.

Br J Pharmacol. 1997 Dec;122(7):1441-9.

6.

The synthesis of 191Pt labelled JM216, an orally active platinum anti-tumour agent.

Bates PI, Sharma HL, Murrer BA, Bernard CF, McAuliffe CA.

Appl Radiat Isot. 1997 Apr;48(4):469-76.

PMID:
9106988
7.

Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.

Raynaud FI, Boxall FE, Goddard P, Barnard CF, Murrer BA, Kelland LR.

Anticancer Res. 1996 Jul-Aug;16(4A):1857-62.

PMID:
8712713
8.

The tissue distribution in BALB/c mice of C-14-labeled JM216, an orally active platinum antitumour compound.

Bates PI, Sharma HL, Murrer BA, McAuliffe CA.

Cancer Chemother Pharmacol. 1996;39(1-2):170-5.

PMID:
8995517
9.

Biotransformation of the platinum drug JM216 following oral administration to cancer patients.

Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CF, Murrer BA, Harrap KR.

Cancer Chemother Pharmacol. 1996;38(2):155-62.

PMID:
8616906
10.

Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.

Goddard PM, Orr RM, Valenti MR, Barnard CF, Murrer BA, Kelland LR, Harrap KR.

Anticancer Res. 1996 Jan-Feb;16(1):33-8.

PMID:
8615631
11.

Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates.

Poon GK, Mistry P, Raynaud FI, Harrap KR, Murrer BA, Barnard CF.

J Pharm Biomed Anal. 1995 Nov;13(12):1493-8.

PMID:
8788134
12.

Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry.

Poon GK, Raynaud FI, Mistry P, Odell DE, Kelland LR, Harrap KR, Barnard CF, Murrer BA.

J Chromatogr A. 1995 Sep 29;712(1):61-6.

PMID:
8556156
13.

DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.

Mellish KJ, Barnard CF, Murrer BA, Kelland LR.

Int J Cancer. 1995 Sep 15;62(6):717-23.

PMID:
7558420
14.

Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.

Kelland LR, Barnard CF, Evans IG, Murrer BA, Theobald BR, Wyer SB, Goddard PM, Jones M, Valenti M, Bryant A, et al.

J Med Chem. 1995 Aug 4;38(16):3016-24.

PMID:
7636864
15.

Bis(acetato)amminedichloro(cyclohexylamine)platinum(IV), an orally active anticancer drug.

Neidle S, Snook CF, Murrer BA, Barnard CF.

Acta Crystallogr C. 1995 May 15;51 ( Pt 5):822-4.

PMID:
7779322
16.

Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents.

Giandomenico CM, Abrams MJ, Murrer BA, Vollano JF, Rheinheimer MI, Wyer SB, Bossard GE, Higgins JD.

Inorg Chem. 1995 Mar;34(5):1015-21. doi: 10.1021/ic00109a004. No abstract available.

PMID:
20000850
17.

A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.

Kelland LR, Barnard CF, Mellish KJ, Jones M, Goddard PM, Valenti M, Bryant A, Murrer BA, Harrap KR.

Cancer Res. 1994 Nov 1;54(21):5618-22.

18.

Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin.

Orr RM, O'Neill CF, Nicolson MC, Barnard CF, Murrer BA, Giandomenico CM, Vollano JF, Harrap KR.

Br J Cancer. 1994 Sep;70(3):415-20.

19.

Preclinical toxicology and tissue platinum distribution of novel oral antitumour platinum complexes: ammine/amine platinum(IV) dicarboxylates.

McKeage MJ, Morgan SE, Boxall FE, Murrer BA, Hard GC, Harrap KR.

Cancer Chemother Pharmacol. 1994;33(6):497-503.

PMID:
8137461
20.

Metal compounds in therapy and diagnosis.

Abrams MJ, Murrer BA.

Science. 1993 Aug 6;261(5122):725-30. Review.

PMID:
8102010
21.

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

Kelland LR, Abel G, McKeage MJ, Jones M, Goddard PM, Valenti M, Murrer BA, Harrap KR.

Cancer Res. 1993 Jun 1;53(11):2581-6.

22.

Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents.

McKeage MJ, Morgan SE, Boxall FE, Murrer BA, Hard GC, Harrap KR.

Br J Cancer. 1993 May;67(5):996-1000.

24.

Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.

Twentyman PR, Wright KA, Mistry P, Kelland LR, Murrer BA.

Cancer Res. 1992 Oct 15;52(20):5674-80.

25.
26.

Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.

De Clercq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H, Balzarini J, Debyser Z, Murrer BA, Schwartz D, et al.

Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5286-90.

27.
28.

Platinum coordination complexes which circumvent cisplatin resistance.

Harrap KR, Kelland LR, Jones M, Goddard PM, Orr RM, Morgan SE, Murrer BA, Abrams MJ, Giandomenico CM, Cobbleigh T.

Adv Enzyme Regul. 1991;31:31-43.

PMID:
1877393
29.

Supplemental Content

Loading ...
Support Center